What happened with AMRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Amneal Pharmaceuticals’ largest business, Affordable Medicines, supplies lower-priced alternatives to branded drugs, including injectables and biosimilars. It makes most of these products itself and sells them to drug wholesalers, pharmacies and other healthcare buyers. It focuses on medicines that are difficult to formulate or manufacture: entering these markets before many competitors arrive can support higher prices, while additional competitors typically push prices down.
The company also sells branded medicines for nervous-system and endocrine disorders through Specialty, including CREXONT, RYTARY and UNITHROID. RYTARY now faces an authorized generic, illustrating how branded sales depend on market exclusivity. Its AvKARE business distributes medicines and medical supplies to U.S. government agencies, especially the Department of Defense and Department of Veterans Affairs, as well as retail and institutional buyers.
Cencora, McKesson Drug, Cardinal Health and CVS Health together provide most of Amneal’s revenue, and none has a long-term agreement guaranteeing future business. Keeping sales flowing depends on timely product launches and reliable, regulator-approved production. FDA approval is required for new products and certain supplier changes, while DEA production quotas limit the supply of controlled-substance products that generate substantial revenue.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Amneal's results hinge on complex generic launches and price erosion, so also watch Sandoz and Hikma, important competitors absent from this list.
Teva competes with Amneal to sell generic medicines and biosimilars to pharmaceutical purchasers, making its launches and pricing relevant to Amneal's sales. Watch Teva's U.S. generic launches and price erosion for signs of pressure on Amneal's Affordable Medicines business.
Viatris competes for Amneal's generic-medicine business across oral medicines, injections and complex dosage forms. Its manufacturing and supply news in these products helps gauge the supply reliability Amneal must match to win purchasers' business.
Dr. Reddy's competes with Amneal for generic-medicine sales by making medicines through integrated operations and pursuing differentiated, first-to-market products. Watch its complex-product launches: new entrants can squeeze the prices and volumes that make Amneal's high-barrier generics attractive.
Amphastar Pharmaceuticals, Inc. competes with Amneal for U.S. sales of technically challenging injectable and nasal medicines. Its launches in these product groups are worth watching because additional competition can pressure Amneal's generic prices and volumes.
ANI Pharmaceuticals, Inc. competes with Amneal for U.S. generic purchasing contracts, including hormonal medicines and medicines formulated to control how quickly they release the drug. Watch ANI's launches and market-share gains in these niches, where price, contract terms and reliable supply decide who wins orders.
Supernus Pharmaceuticals, Inc. and Amneal both sell Parkinson's medicines, so adoption of Supernus's treatments matters to Amneal's branded CNS business. Competition also runs the other way: after Amneal launched generic Namzaric in January 2025, Supernus's acquired Adamas business expected no further royalties on U.S. Namzaric sales.
Jazz Pharmaceuticals competes with Amneal's generic sodium oxybate for U.S. narcolepsy patients through its branded Xyrem and Xywav medicines. Watch Jazz's sales of those two products among narcolepsy patients for evidence of generic penetration; Amneal's volume-limited right to sell against historical Xyrem sales ended at year-end 2025.
Alkermes Inc. plc faces Amneal's generic injectable risperidone in the schizophrenia market, where Alkermes sells ARISTADA, and has licensed Amneal to sell a future U.S. generic version of VIVITROL. Watch VIVITROL generic-entry news for Amneal's next sales opportunity, distinct from the injectable competition already under way.
Bausch Health's patent case stands between Amneal and sales of its proposed generic Xifaxan, a gastrointestinal medicine accounting for approximately 85% of Bausch's U.S. Salix revenue. Watch the litigation and final FDA approval: Amneal received tentative approval in January 2025, but final approval remained blocked by a court order.
Pfizer competes with Amneal in generic medicines but also controls the Metsera collaboration for medicines to be made at funded Amneal facilities. Pfizer shortened the term to four years from first commercial sale and eliminated agreed rebates and commercial-product payments to Amneal, while leaving construction funding of up to $100 million for two Indian facilities intact, subject to annual caps.
ARS Pharmaceuticals, Inc.'s needle-free neffy competes with Amneal's injectable Adrenaclick for emergency epinephrine use, with ARS selling primarily to U.S. drug wholesalers. Watch neffy's uptake and reimbursement coverage to gauge the competitive appeal of avoiding an injection versus Amneal's product.
Bausch Health Companies Inc earningsBHC
Bausch Health’s report may clarify whether the court and FDA barriers still keep Amneal Pharmaceuticals’ proposed generic Xifaxan from reaching the market.
Watch for Bausch Health’s litigation update and whether the court order still blocks final FDA approval. If the barrier remains, Amneal cannot turn this proposed generic into sales; if it is cleared, the opportunity can move forward, though that does not mean an immediate launch.
Amneal Pharmaceuticals, Inc. earningsThis company
Amneal Pharmaceuticals’ report will show whether sales from new and complex generics can offset price pressure on its Affordable Medicines business.
Read Affordable Medicines revenue alongside its gross margin. Revenue growth with a steady margin would show that new products and volume are offsetting price erosion; growth with a falling margin would show discounts are eating into the gain. Together, the figures show whether this business is turning sales growth into better economics.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report will show whether its U.S. generic launches and pricing are intensifying competition for Amneal Pharmaceuticals’ purchaser orders.
Look at Teva’s U.S. generic launches and pricing. More new competitors and further price declines would give purchasers such as wholesalers more alternatives, making it harder for Amneal’s Affordable Medicines business to retain orders and gross margin; steadier competition and prices would mean less pressure from this rival.
